Session

Back to Programme Overview

Treatment of high risk and oligo-metastatic prostate cancer

Poster Session 02

  • Location:
    Room Amsterdam, North Hall (Level 1)
  • Chairs:
     B.J. Challacombe, London (GB)
     S. Egawa, Tokyo (JP)
     R.J. Karnes, Rochester (US)
  • Aims and objectives of this session

    The aim of this session is to evaluate outcomes of treatments in high risk and oligo-metastatic prostate cancer

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
17
Attempted nerve sparing in high risk prostate cancer: Does it have an impact on oncological and functional outcomes? A retrospective long-term single center study

By: Furrer M.A.1, Gross T.1, Nguyen D.P.1, Boxler S.1, Genitsch V.2, Burkhard F.1, Thalmann G.1

Institutes: 1University Hospital Bern, Dept. of Urology, Bern, Switzerland, 2University Hospital Bern, Institute of Pathology, Bern, Switzerland

18
Impact of preoperative risk on metastatic progression and cancer specific death in patients with adverse pathology at radical prostatectomy

By: Boehm K.1, Leyh-Bannurah S-R.2, Rosenbaum C.2, Budäus L.3, Graefen M.3, Haferkamp A.1, Tilki D.3

Institutes: 1University Medical Center, Johannes Gutenberg University, Dept. of Urology and Pediatric Urology, Mainz, Germany, 2University Medical Center, Dept. of Urology, Hamburg, Germany, 3University Medical Center, Martini-Clinic, Hamburg, Germany

19
Low rate of positive surgical margins are not associated with improved biochemical recurrence in high-risk prostate cancer patients

By: Srougi V.1, Sanchez-Salas R.1, Secin F.2, Baghdadi M.1, Nunes-Silva I.1, Garcia-Barreras S.1, Rembeyo G.1, Rozet F.1, Galiano M.1, Barret E.1, Cathelineau X.1

Institutes: 1Institut Montsouris, Dept. of Urology, Paris, France, 2CEMIC and San Lazaro Foundation, Dept. of Urology, Buenos Aires, Argentina

20
Association between type 2 diabetes and curative treatment in men with intermediate and high risk localised prostate cancer

By: Crawley D.1, Garmo H.1, Rudman S.2, Stattin P.3, Zethelius B.4, Holmberg L.1, Adolfsson J.4, Van Hemelrijck M.1

Institutes: 1King’s College London, Dept. of Cancer Epdiemiology, London, United Kingdom, 2Guy’s and St Thomas NHS Foundation Trust, Dept. of Medical Oncology, London, United Kingdom, 3Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, 4Karolinska Institute, Dept. of Clinical Science, Intervention and Technology, Stockholm, Sweden

21
Improved recurrence-free survival in locally advanced prostate cancer after robot-assisted radical prostatectomy with 3D-cancer mapping constructed by MRI/US fusion biopsy

By: Kamoi K., Okihara K., Hongo F., Naitoh Y., Iwata A., Kanazawa M., Ushijima S., Ukimura O.

Institutes: Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan

22
Assessing the 20-year outcomes of radical prostatectomy for high risk prostate cancer: Results from a large, multi-institutional series

By: Bianchi M.1, Colicchia M.3, Gandaglia G.2, Munegato S.4, Fossati N.2, Bandini M.2, Stabile A.2, Dell’Oglio P.2, Suardi N.2, Gontero P.4, Karnes J.3, Joniau S.5, Spahn M.6, Montorsi F.2, Briganti A.2

Institutes: 1Magna Graecia University, Dept. of Urology, Catanzaro, Italy, 2Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 3Mayo Clinic, Dept. of Urology, Rochester, United States of America, 4Molinette Hospital, Dept. of Urology, Turin, Italy, 5University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 6University Hospital of Bern, Dept. of Urology, Bern, Switzerland

23
Oncological and functional outcomes after RP for high or very high-risk prostate cancer – European validation of the current NCCN guideline

By: Pompe R.S.1, Gild P.2, Chun F.2, Salomon G.1, Leyh-Bannurah S-R.1, Huland H.1, Graefen M.1, Karakiewicz P.3, Tilki D.1

Institutes: 1Universitätsklinikum Hamburg-Eppendorf, Martini Clinic and Dept. of Urology, Hamburg, Germany, 2Universitätsklinikum Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 3University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada

24
Freedom from androgen deprivation and radiotherapy therapy after upfront minimally invasive surgery for high-risk prostate cancer

By: Servián Vives P., Patel A., Winkler M.

Institutes: Imperial College Nhs Trust, Dept. of Urology, London, United Kingdom

25
Survival associated with radical prostatectomy versus radiotherapy for high-risk prostate cancer: A contemporary, nationwide observational analysis

By: Jindal T., Dalela D., Karabon P., Vetterlein M., Seisen T., Sood A., Trinh Q-D., Jeong W., Menon M., Abdollah F.

Institutes: Henry Ford Hospital, Dept. of Urology, Detroit, United States of America

26
Impact of additional radiation and/or androgen deprivation therapy on functional outcomes after radical prostatectomy

By: Tennstedt P.1, Adam M.2, Tilki D.1, Steuber T.1, Haese A.1, Salomon G.1, Petersen C.3, Huland H.1, Graefen M.1, Huber W.4, Schlomm T.1

Institutes: 1University Medical Center Eppendorf, Martini-Klinik, Hamburg, Germany, 2University of Tübingen, Dept. of Urology, Tübingen, Germany, 3University Medical Center Eppendorf, Dept. of Radiooncology, Hamburg, Germany, 4European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Hamburg, Germany

27
Extended pelvic lymph node dissection for intermediate-high risk prostate cancer: Frequency and distribution of nodal metastases

By: Roscigno M.1, Nicolai M.1, Naspro R.1, Pellucchi F.1, Cornaghi L.B.1, Angiolilli D.1, Chinaglia D.2, Da Pozzo L.F.1

Institutes: 1ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy, 2ASST Papa Giovanni XXIII, Dept. of Pathology, Bergamo, Italy

28
Predictors of early cancer specific and other cause mortality in high risk prostate cancer patients after radical prostatectomy: Results from a large, multi-institutional analysis

By: Bianchi M.1, Gandaglia G.1, Fossati N.1, Dell’Oglio P.1, Joniau S.2, Colicchia M.3, Munegato S.4, Bandini M.5, Spahn M.6, Scattoni V.5, Gontero P.4, Karnes J.3, Montorsi F.5, Briganti A.5

Institutes: 1Vita-Salute University San Raffaele; Magna Graecia University, Dept. of Urology, Milan, Italy, 2University Hospital of Leuven, Dept. of Urology, Leuven, Belgium, 3Mayo Clinic, Dept. of Urology, Rochester, United States of America, 4University of Turin, Dept. of Urology, Turin, Italy, 5Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 6University Hospital of Bern, Dept. of Urology, Bern, Switzerland

29
Cytoreductive radical prostatectomy (cRP) is feasible in men with hormone-naive, metastatic prostate cancer (mPCA)

By: Heidenreich A.1, Briganti A.2, Karnes J.3, Fossati N.2, Gandaglia G.2, Montorsi F.2, Suardi N.2, Colicchia M.3, Shariat S.4, Pfister D.1

Institutes: 1Uniklinik Köln, Dept. of Urology, Cologne, Germany, 2Vita Salute San Raffaele University, Urological Research Institute, Milan, Italy, 3Mayo Clinic, Dept. of Urology, Rochester, United States of America, 4Universitätsklinik Wien, Dept. of Urology, Vienna, Austria

30
Robot assisted radical prostatectomy in patients with oligometastatic prostate cancer

By: Jang W.S.1, Heo J.E.1, Oh K.T.1, Kim M.S.1, Kang D.H.1, Jeong W.S.1, Ham W.S.1, Kim Y.S.2, Cho I.R.3, Choi Y.D.1

Institutes: 1Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, South Korea, 2National Health Insurance Corporation Ilsan Hospital, Dept. of Urology and Urological Science Institute, Goyang, South Korea, 3Inje University College of Medicine, Dept. of Urology and Urological Science Institute, Gimhae, South Korea

31
Observation of preliminary clinical effect and analysis of perioperative complications of radical prostatectomy for patients with oligo-metastatic prostate cancer

By: Li G., Dai B., Ye D.

Institutes: Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China